STAAR Surgical Appoints David Bailey as Chief Commercial Officer

What Happened

• STAAR Surgical Company (STAA) filed an 8-K reporting that it appointed David Bailey as Chief Commercial Officer, effective September 8, 2026. Mr. Bailey has advised the company through his Switzerland-based firm DB Consulting since 2010 and previously served as STAAR’s CEO & President (2001–2008) and President, International Operations (2008–2011). The company and Mr. Bailey executed an Offer Letter dated September 4, 2026 (filed as Exhibit 10.1).

Key Details

• Start date / effective: September 8, 2026 (appointment announced Sept. 8; 8-K filed Sept. 10, 2026).
• Cash compensation: base salary CHF 462,825 (~$575,000) annually, prorated for 2026; eligible for annual cash bonus with a 2026 target equal to 60% of base, prorated.
• Equity awards: initial RSU grant valued at $850,000 vesting over three years (1/3 each anniversary); 2026 long‑term incentive award valued at $1,400,000 (prorated) split 50% stock options / 50% RSUs.
• Other: will participate in standard executive benefits and severance/change‑in‑control arrangements; press release filed as Exhibit 99.1.

Why It Matters

• This is a material executive appointment with a seasoned leader who has prior top-level experience at STAAR and a recent advisory relationship with the company. The compensation package includes substantial equity and option awards, which align his pay with company performance but can contribute to future share dilution and compensation expense. Investors should note the prorated cash and incentive amounts for 2026 and that the offer letter is publicly filed for review.